Erythromelalgia during Infliximab Induction Therapy for Ulcerative Colitis: A Case Report and Literature Review
Syrine Hamada *
Department of Dermatology, Mohammed V University Souissi, Rabat Institute, Ibn Sina University Hospital, Rue Lamfadel Cherkaoui, P.O. Box 6527, Rabat, Morocco.
Nadia Ismaili
Department of Dermatology, Mohammed V University Souissi, Rabat Institute, Ibn Sina University Hospital, Rue Lamfadel Cherkaoui, P.O. Box 6527, Rabat, Morocco.
Mariame Meziane
Department of Dermatology, Mohammed V University Souissi, Rabat Institute, Ibn Sina University Hospital, Rue Lamfadel Cherkaoui, P.O. Box 6527, Rabat, Morocco.
Laila Benzekri
Department of Dermatology, Mohammed V University Souissi, Rabat Institute, Ibn Sina University Hospital, Rue Lamfadel Cherkaoui, P.O. Box 6527, Rabat, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Background: Erythromelalgia is a rare neurovascular disorder characterised by episodes of burning pain and erythema of the extremities. Secondary forms are mainly associated with myeloproliferative neoplasms, autoimmune diseases and drugs. To our knowledge, only two cases attributed to anti-tumour necrosis factor (TNF) alpha therapy have been published, both in patients with Crohn's disease.
Case Presentation: A 19-year-old student whose ulcerative colitis presented as acute severe colitis received corticosteroids and mesalazine, followed by induction therapy with infliximab. One week after the second infusion, during corticosteroid tapering, she developed intense burning pain and tingling of both feet, relieved only by prolonged immersion in ice water. All treatments were stopped. Examination showed bilateral oedema, a symmetrical erythema extending to the lower legs and papules, some of which were ulcerated.
Blood count, vitamin B levels, thyroid function, HIV serology, immunological tests and electroneuromyography were normal, and there was no diabetes mellitus. Erythromelalgia secondary to infliximab was diagnosed and reported to pharmacovigilance. Pregabalin was partially effective; switching to gabapentin resolved pain and erythema within one week. Treatment was tapered from the fourth month, another anti-TNF agent was later introduced, and no recurrence occurred after eight months.
Conclusion: Erythromelalgia is a rare neurocutaneous adverse event of anti-TNF agents. Purpura or ulceration should prompt the exclusion of a drug-induced vasculitis and of cold-induced skin injury. Early recognition allows symptomatic treatment and guides the choice of the next biologic.
Keywords: Drug-related side effects and adverse reactions, erythromelalgia, gabapentin, infliximab, tumor necrosis factor inhibitors, ulcerative colitis